Marieke van Son

75 FOCAL SALVAGE TREATMENT: A NARRATIVE REVIEW REFERENCES 1. Cornford, P.; Bellmunt, J.; Bolla, M.; Briers, E.; De Santis, M.; Gross, T.; Henry, A.M.; Joniau, S.; Lam, T.B.; Mason, M.D., et al. Eau-estro-siog guidelines on pros- tate cancer. Part ii: Treatment of relaps- ing, metastatic, and castration-resistant prostate cancer. Eur Urol 2017, 71, 630- 642; DOI: 10.1016/j.eururo.2016.08.002. 2. Hamdy, F.C.; Donovan, J.L.; Lane, J.A.; Mason, M.; Metcalfe, C.; Holding, P.; Davis, M.; Peters, T.J.; Turner, E.L.; Martin, R.M., et al. 10-year outcomes after monitoring, surgery, or radiothera- py for localized prostate cancer. N Engl J Med 2016, 375, 1415-1424; DOI: 10.1056/ NEJMoa1606220. 3. Sheets, N.C.; Goldin, G.H.; Meyer, A.M.; Wu, Y.; Chang, Y.; Sturmer, T.; Holmes, J.A.; Reeve, B.B.; Godley, P.A.; Carpen- ter, W.R., et al. Intensity-modulated ra- diation therapy, proton therapy, or con- formal radiation therapy and morbidity and disease control in localized prostate cancer. Jama 2012, 307, 1611-1620; DOI: 10.1001/jama.2012.460. 4. Biegala, M.; Hydzik, A. Analysis of dose distribution in organs at risk in patients with prostate cancer treated with the intensity-modulated radiation therapy and arc technique. Journal of med- ical physics 2016, 41, 198-204; DOI: 10.4103/0971-6203.189490. 5. Aluwini, S.; Pos, F.; Schimmel, E.; van Lin, E.; Krol, S.; van der Toorn, P.P.; de Jager, H.; Dirkx, M.; Alemayehu, W.G.; Hei- jmen, B., et al. Hypofractionated versus conventionally fractionated radiother- apy for patients with prostate cancer (hypro): Acute toxicity results from a randomised non-inferiority phase 3 trial. The Lancet. Oncology 2015, 16, 274-283; DOI: 10.1016/S1470-2045(14)70482-6. 6. Aluwini, S.; Pos, F.; Schimmel, E.; Krol, S.; van der Toorn, P.P.; de Jager, H.; Alemayehu, W.G.; Heemsbergen, W.; Heijmen, B.; Incrocci, L. Hypofraction- ated versus conventionally fractionated radiotherapy for patients with prostate cancer (hypro): Late toxicity results from a randomised, non-inferiority, phase 3 trial. The Lancet. Oncology 2016, 17, 464-474; DOI: 10.1016/S1470- 2045(15)00567-7. 7. Dearnaley, D.; Syndikus, I.; Mossop, H.; Khoo, V.; Birtle, A.; Bloomfield, D.; Graham, J.; Kirkbride, P.; Logue, J.; Malik, Z., et al. Conventional versus hypofrac- tionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-infe- riority, phase 3 chhip trial. The Lancet. Oncology 2016, 17, 1047-1060; DOI: 10.1016/S1470-2045(16)30102-4. 8. Musunuru, H.B.; Quon, H.; Davidson, M.; Cheung, P.; Zhang, L.; D’Alimonte, L.; Deabreu, A.; Mamedov, A.; Loblaw, A. Dose-escalation of five-fraction sabr in prostate cancer: Toxicity compari- son of two prospective trials. Radiother Oncol 2016, 118, 112-117; DOI: 10.1016/j. radonc.2015.12.020. 9. Catton, C.N.; Lukka, H.; Gu, C.S.; Martin, J.M.; Supiot, S.; Chung, P.W.M.; Bauman, G.S.; Bahary, J.P.; Ahmed, S.; Cheung, P., et al. Randomized trial of a hypof- ractionated radiation regimen for the treatment of localized prostate cancer. Journal of clinical oncology : official journal of the American Society of Clin- ical Oncology 2017, 35, 1884-1890; DOI: 10.1200/JCO.2016.71.7397. 10. Dearnaley, D.; Hall, E. How will the chhip trial affect the future of prostate radiotherapy? Expert review of anti- cancer therapy 2018, 18, 607-609; DOI: 10.1080/14737140.2018.1477595. 4